Bladder-specific Knockout and Gene Expression

膀胱特异性敲除和基因表达

• 批准号: 7434569
• 负责人: XUE-RU WU
• 金额: $ 26.45万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-01 至 2010-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7434569
• 关键词: Ablation; Achondroplasia; Address; Animal Model; Apoptosis; Biological; Biological Models; Biology; Bladder; Bladder Neoplasm; Chondrocytes; Differentiation and Growth; Disease; Dose; Doxycycline; Dwarfism; Embryo; Epithelium; Fibroblast Growth Factor Receptors; Functional disorder; Gene Activation; Gene Expression; Generations; Genes; Genetic Recombination; Germ-Line Mutation; Goals; Growth; Healthcare; Human; Interstitial Cystitis; Invasive; Knock-out; LacZ Genes; Lead; Malignant Neoplasms; Malignant neoplasm of urinary bladder; Mediating; Molecular; Mus; Mutation; Neonatal; Oncogenes; Oncogenic; Papillary; Papillary Neoplasm; Pathogenesis; Pathway interactions; Pre-Clinical Model; Process; Property; Reaction Time; Reporter; Reporter Genes; Research; Response Elements; Retinoblastoma Genes; Role; Series; Signal Pathway; Signaling Molecule; Site; Skeletal Development; Skeletal system; Somatic Mutation; System; Testing; Tetanus Helper Peptide; Tetracycline; Tetracycline Control; Tetracyclines; Thanatophoric Dysplasia; Time; Trans-Activators; Transgenes; Transgenic Mice; Transgenic Model; Transgenic Organisms; Tumor Suppressor Genes; Tumor Suppressor Proteins; UPK2 gene; United States; Urinary tract infection; Urologic Diseases; Urothelium; Withdrawal; Work; base; cost; experience; fibroblast growth factor receptor 3; in vivo; insight; interest; knockout gene; malformation; mature animal; mouse model; mutant; novel; promoter; recombinase; tool; tumor; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): Bladder epithelium or urothelium is involved in major urinary tract diseases including bladder cancer, urinary tract infection and interstitial cystitis. However, research into the molecular bases of urothelial diseases has been hampered by the lack of effective model systems. Utilizing uroplakin II (UPII) gene promoter, we have succeeded over the last several years in targeting gene expression specifically into the urothelium of transgenic mice. The existing system, however, does not allow gene expression and inactivation to occur in a temporally controlled fashion, thus precluding many biological questions from being addressed. The overall goals of the current project are to develop and validate the second-generation transgenic systems that will allow urothelium-specific and inducible gene expression as well as knockout; and to utilize these novel systems to study the in vivo roles of several critical genes in urothelial growth, differentiation and tumorigenesis. Toward these goals, we plan to carry out two series of studies. In the first, we will generate transgenic lines in which the UPII promoter drives the urothelium-specific expression of a reverse tetracycline transactivator (UPll/rtTA). We will then test the feasibility and parameters of urothelium-specific and inducible gene expression by crossing UPll/rtTA mice with TRE/LacZ reporter mice so that LacZ expression is under the control of tetracycline response elements (TRE) and only occurs upon doxycycline treatment. In addition, we will establish a urothelium-specific and inducible knockout system, by crossing the UPll/rtTA mice with TRE/Cre mice. We will then test the functionality of this system by crossing the UPll/rtTA-TRE/Cre bi-transgenic mice with Rosa26 reporter mice in which the reporter genes are transcriptionally activated upon Cre expression. This system will allow inducible knockout of any genes of interest in the urothelium. In the second series of studies, we will inducibly express an activated fibroblast growth factor receptor as well as inducibly delete the retinoblastoma gene in the urothelium and test the hypothesis that the two genetic alterations induce low-grade superficial papillary tumors and high-grade invasive tumors, respectively. We will also examine the signaling pathways that these genetic alterations exploit in transforming the urothelium. These studies will generate powerful experimental tools for studying bladder biology and diseases and offer molecular insights regarding urothelial growth and tumorigenesis.

描述（由申请人提供）：膀胱上皮或尿路上皮参与主要尿路疾病，包括膀胱癌，尿路感染和间质性膀胱炎。然而，缺乏有效的模型系统阻碍了尿路上皮疾病的分子碱基的研究。利用乌罗列汀II（UPII）基因启动子，我们在过去的几年中取得了成功的靶向基因表达，专门针对转基因小鼠的尿皮细胞。但是，现有的系统不允许以时间控制的方式发生基因表达和灭活，因此排除了许多生物学问题的解决。当前项目的总体目标是开发和验证第二代转基因系统，这些系统将允许尿路上皮特异性和可诱导的基因表达以及敲除；并利用这些新型系统来研究几个关键基因在尿路上皮生长，分化和肿瘤发生中的体内作用。朝向这些目标，我们计划进行两项系列研究。首先，我们将生成转基因线，其中UPII启动子驱动反向四环素反式激活器（UPLL/RTTA）的尿路上皮特异性表达。然后，我们将通过将UPLL/RTTA小鼠与TRE/LACZ Reporter小鼠跨越UPLL/RTTA小鼠的可行性和参数，以使LACZ表达在Tetracycline响应元件（TRE）的控制之下，并且仅在DoxyCycyCycycycycycyle处理后发生。此外，我们将通过用TRE/CRE小鼠跨越UPLL/RTTA小鼠来建立一个尿皮上特异性和诱导的敲除系统。然后，我们将通过与ROSA26报告基因小鼠跨越UPLL/RTTA-TRE/CRE BI-TRANSGENIC小鼠来测试该系统的功能，其中记者基因在CRE表达时被转录激活。该系统将允许在尿路上皮中诱导的任何感兴趣的基因。在第二系列的研究中，我们将诱导表达活化的成纤维细胞生长因子受体，并在尿皮上诱导删除卵线皮细胞瘤基因，并检验两种遗传变化诱导低度浅层乳头状肿瘤和高级侵入性肿瘤的假设。我们还将检查这些遗传改变在转化尿路上皮时利用的信号传导途径。这些研究将生成强大的实验工具，用于研究膀胱生物学和疾病，并提供有关尿路上皮生长和肿瘤发生的分子见解。